[1]张宪波,刘月皎,陈云峰.粪便钙卫蛋白在肠易激综合征和炎症性肠病鉴别诊断中的意义分析[J].现代检验医学杂志,2021,36(01):124-127.[doi:10.3969/j.issn.1671-7414.2021.01.031]
 ZHANG Xian-bo,LIU Yue-jiao,CHEN Yun-feng.Significance of Fecal Calprotectin in Differential Diagnosis of Irritable Bowel Syndrome and Inflammatory Bowel Disease[J].Journal of Modern Laboratory Medicine,2021,36(01):124-127.[doi:10.3969/j.issn.1671-7414.2021.01.031]
点击复制

粪便钙卫蛋白在肠易激综合征和炎症性肠病鉴别诊断中的意义分析()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年01期
页码:
124-127
栏目:
检验与临床
出版日期:
2021-02-05

文章信息/Info

Title:
Significance of Fecal Calprotectin in Differential Diagnosis of Irritable Bowel Syndrome and Inflammatory Bowel Disease
文章编号:
1671-7414(2021)01-124-04
作者:
张宪波刘月皎陈云峰
(南京中医药大学附属江苏省中医院检验科,南京 210029)
Author(s):
ZHANG Xian-bo LIU Yue-jiao CHEN Yun-feng
(Department of Clinical Laboratory, Jiangsu Provincial Hospital of TCM Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing 210029,China)
关键词:
粪便钙卫蛋白肠易激综合征炎症性肠病鉴别
分类号:
R574;R446.13
DOI:
10.3969/j.issn.1671-7414.2021.01.031
文献标志码:
A
摘要:
目的 探讨粪便钙卫蛋白( fecal calprotectin,FC)在肠易激综合征( irritable bowel syndrome,IBS)和炎症性肠病( in.ammatory bowel disease,IBD)鉴别诊断中的意义。方法 选择 2018年 1月~ 7月江苏省中医院门诊及病房收治的 IBS患者 38例,IBD患者 114例。IBD病例中包含溃疡性结肠炎 (ulcerative colitis,UC)63例,克罗恩病 (Crohn’s disease,CD)51例。收集同期健康体检者 55例作为健康对照。采用酶联免疫吸附试验( ELISA)测定 FC水平,并同时检测 IBD患者红细胞沉降率( ESR)及 C反应蛋白( CRP),分析各组之间 FC水平差异,以及 FC,ESR和 CRP与疾病活动指数的相关性。结果 IBD患者 FC水平显著高于 IBS组及健康对照组 , 差异有统计学意义( q=15.897,18.523,均 P <0.01),UC组 FC水平高于 CD组,差异有统计学意义( q=5.204,P <0.01);IBS组 FC水平和健康组相比,差异无统计学意义( q=0.318,P >0.05)。受试者工作曲线( ROC)分析显示 FC升高的临界值为 159.5μg/g,对应诊断 IBD的最佳灵敏度和特异度分别为 91.2%和 94.7%。UC组 FC,ESR和 CRP与 Mayo评分均呈正相关性( r=0.851,0.752和 0.531,均 P <0.01);CD组 FC,ESR和 CRP与克罗恩病活动指数( CDAI)评分相关系数均呈正相关性( r=0.796,0.693和 0.476, 均 P <0.01)。活动期 UC和 CD组患者经过治疗后,FC水平显著降低(t=17.543,11.313,均 P <0.01)。结论  FC可作为鉴别 IBS和 IBD以及判断 IBD活动性和疗效的一个良好指标。

参考文献/References:

[1] DEFREES D N, BAILEY J. Irritable bowel syndrome: epidemiology, pathophysiology, diagnosis, and treatment[J]. Primary Care, 2017, 44(4):655-671.
[2] POPA S L, LEUCUTA D C, DUMITRASCU D L. Pressure management as an occupational stress risk factor in irritable bowel syndrome: A cross-sectional study[J]. Medicine, 2018, 97(49): e13562.
[3] AYLING R M, KOK K. Fecal calprotectin[J]. Advances in Clinical Chemistry, 2018, 87: 161-190.
[4] BROOKES M J, WHITEHEAD S, GAYA D R, et al. Practical guidance on the use of faecal calprotectin[J]. Frontline Gastroenterology, 2018, 9(2): 87-91.
[5] DAI Cong, JIANG Min, SUN Mingjun. Fecal markers in the management of in.ammatory bowel disease[J]. Postgraduate Medicine, 2018, 130(7): 597-606.
[6] 中华医学会消化病学分会炎症性肠病学组.炎症性肠病诊断与治疗的共识意见 (2018年·北京 )[J].中华消化杂志,2018, 38 (5): 292-311. Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018) [J]. Chinese Journal of Digestion, 2018, 38 (5): 292-311.
[7] VIVINUS-NéBOT M, FRIN-MATHY G, BZIOUEC-HE H, et al. Functional bowel symptoms in quiescent in.ammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation[J]. Gut, 2014, 63(5): 744-752.
[8] JONSSON N, NILSEN T, GILLE-JOHNSON P, et al. Calprotectin as an early biomarker of bacterial infections in critically ill patients: an exploratory cohort assessment[J]. Critical Care and Resuscitation : Journal of the Australasian Academy of Critical Care Medicine, 2017, 19(3): 205-213.
[9] D’HAENS G, FERRANTE M, VERMEIRE S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in in.ammatory bowel disease[J]. In.ammatory Bowel Diseases, 2012, 18(12): 2218-2224.
[10] 朱益佳 , 宁明哲 , 杨平 , 等 .血清炎症性肠病抗体谱的检测对 IBD诊断及鉴别诊断的临床价值 [J].现代检验医学杂志 , 2017, 32(1):141-143. ZHU Yijia,NING Mingzhe,YANG Ping, et al. Clinical value of diagnosis and differential diagnosis of detection of serum inflammatory bowel disease antibody spectrum in IBD[J].Journal of Modern Laboratory Medicine, 2017,32(1):141-143.
[11] GECSE K B, BRANDSE J F, VAN WILPE S, et al. Impact of disease location on fecal calprotectin levels in Crohn’s disease[J]. Scandinavian Journal of Gastroenterology, 2015, 50(7): 841-847.
[12] LOPES S, ANDRADE P, AFONSO J, et al. Monitoring Crohn’s disease activity: endoscopy, fecal markers and computed tomography enterography[J]. Therapeutic Advances in Gastroenterology, 2018, 11: 1756284818769075.
[13] PUOLANNE A M, KOLHO K L, ALFTHAN H, et al. Rapid fecal calprotectin test and symptom index in monitoring the disease activity in colonic in.ammatory bowel disease[J]. Digestive Diseases and Sciences, 2017, 62(11): 3123-3130.
[14] FADEEVA N A, KORNEEVA I A, KNYAZEV O V, et al. Biomarkers of in.ammatory bowel disease activity[J]. Terapevticheskii Arkhiv, 2018, 90(12): 107-111.
[15] 曾俊祥 , 吕婕 , 罗婷 , 等 .粪便钙卫蛋白检测及其实验影响因素 [J].临床检验杂志 ,2019,37(10):756-759. ZENG Junxiang,Lü Jie,LUO Ting, et al.Detection of fecal calprotectin and its experimental influencing factors[J]. Chinese Journal of Clinical Laboratory Science,2019,37(10):756-759.

备注/Memo

备注/Memo:
作者简介:张宪波(1984-),男,大学本科,研究方向:医学免疫学, E-mail:402751551@qq.com。
通讯作者:陈云峰,副主任技师,E-mail: 438854599@qq.com。
更新日期/Last Update: 2021-02-05